Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy

Core Insights - Abeona Therapeutics has activated Children's Hospital Colorado as a Qualified Treatment Center for ZEVASKYN, a gene-modified therapy for recessive dystrophic epidermolysis bullosa (RDEB) [1][2] - ZEVASKYN is the first FDA-approved therapy for treating wounds in RDEB patients, offering a long-lasting treatment option and improved quality of life [2][5] - The collaboration aims to broaden access to ZEVASKYN across a network of established epidermolysis bullosa centers [2] Company Overview - Abeona Therapeutics is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases, with ZEVASKYN being its flagship product [11] - The company operates a cGMP manufacturing facility in Cleveland, Ohio, which is responsible for the commercial production of ZEVASKYN [11] Product Details - ZEVASKYN (prademagene zamikeracel) is an autologous cell sheet-based gene therapy designed to treat wounds in both adult and pediatric patients with RDEB [6][5] - The therapy incorporates the COL7A1 gene into a patient's skin cells to produce functional type VII collagen, which is essential for skin integrity [5][6] - Clinical results have shown meaningful wound healing and pain reduction with a single application of ZEVASKYN [5] Clinical and Research Context - Children's Hospital Colorado is recognized as a center of excellence for epidermolysis bullosa and is part of the EB Clinical Research Consortium, contributing to advanced research and treatment options [2][10] - The hospital's Precision Medicine Institute supports innovative treatments by utilizing patients' unique genetic information [2] Patient Support Services - Abeona offers a comprehensive patient support program called Abeona Assist, which helps patients navigate insurance benefits, financial assistance, and logistical support for treatment [3]